1. Home
  2. PLUN vs VANI Comparison

PLUN vs VANI Comparison

Compare PLUN & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLUN

Plutonian Acquisition Corp II

N/A

Current Price

$10.06

Market Cap

141.6M

Sector

N/A

ML Signal

N/A

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

N/A

Current Price

$1.26

Market Cap

119.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUN
VANI
Founded
N/A
1998
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.6M
119.0M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
PLUN
VANI
Price
$10.06
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.50
AVG Volume (30 Days)
29.7K
211.9K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$0.92
52 Week High
$10.10
$1.92

Technical Indicators

Market Signals
Indicator
PLUN
VANI
Relative Strength Index (RSI) 60.35 42.55
Support Level $9.97 $1.13
Resistance Level $10.10 $1.25
Average True Range (ATR) 0.00 0.07
MACD 0.00 -0.01
Stochastic Oscillator 55.56 20.58

Price Performance

Historical Comparison
PLUN
VANI

About PLUN Plutonian Acquisition Corp II

Plutonian Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Share on Social Networks: